The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guérin (BCG) for...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adults with unresectable or metastatic triple-negative breast cancer (TNBC)...
An antibody-drug conjugate is approved to treat early-stage breast cancer, and preventive blood thinners linked to fewer blood clots.
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting 2026 enabling new insights into cancer.
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for two indications in adult patients...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More